Keyphrases
High Risk
100%
Radiosensitization
100%
Docetaxel
100%
Meningioma
100%
Methylation Profile
100%
Meningioma Cells
42%
Chemotherapy
28%
DNA Methylation (DNAm)
14%
Clinically Significant
14%
Cell Source
14%
Tumor
14%
Radiotherapy
14%
Patient-derived
14%
Inhibitory Effect
14%
Apoptosis Markers
14%
FDA-approved Drugs
14%
Recurring
14%
After Surgery
14%
Progression-free Survival
14%
Molecular Pathways
14%
Methylation
14%
Fast-growing
14%
DNA Double-strand Breaks
14%
Cellular Pathways
14%
Tumor Grade
14%
IC50 Value
14%
Existing Drugs
14%
Radiation Therapy
14%
CpG Sites
14%
Cancer Drugs
14%
Significant Disabilities
14%
CpG Methylation
14%
Clinical Analysis
14%
Radiation Sensitivity
14%
DNA Methylation Profiling
14%
High-risk Cases
14%
Global Patterns
14%
Genomic DNA Methylation
14%
Tumor Doubling Time
14%
Primary Intracranial Tumours
14%
Maximal Benefit
14%
Standard-of-care Chemotherapies
14%
Medicine and Dentistry
Meningioma
100%
Radiosensitizer
100%
Methylation
100%
Docetaxel
100%
Neoplasm
33%
DNA Methylation
22%
Radiation Therapy
22%
Progression Free Survival
11%
Genomic DNA
11%
In Vitro
11%
Intracranial Tumor
11%
Programmed Cell Death
11%
Malignant Neoplasm
11%
Meningioma Cell Line
11%
Radiosensitivity
11%
IC50
11%
Double-Strand DNA Break
11%
Neuroscience
Docetaxel
100%
Radiosensitizer
100%
Meningioma
100%
Methylation
100%
DNA Methylation
20%
Radiation Therapy
20%
In Vivo
10%
Cell Line
10%
CpG Site
10%
In Vitro
10%
Genomic DNA
10%
Double Stranded DNA Break
10%
Intracranial Tumor
10%
Programmed Cell Death
10%
Pharmacology, Toxicology and Pharmaceutical Science
Radiosensitizing Agent
100%
Docetaxel
100%
Meningioma
100%
Chemotherapy
30%
Neoplasm
30%
Malignant Neoplasm
10%
Progression Free Survival
10%
Genomic DNA
10%
Double Stranded DNA
10%
Intracranial Tumor
10%
IC50
10%